DE30815T1 - Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches prothymozyt-antigen - Google Patents

Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches prothymozyt-antigen

Info

Publication number
DE30815T1
DE30815T1 DE198080304350T DE80304350T DE30815T1 DE 30815 T1 DE30815 T1 DE 30815T1 DE 198080304350 T DE198080304350 T DE 198080304350T DE 80304350 T DE80304350 T DE 80304350T DE 30815 T1 DE30815 T1 DE 30815T1
Authority
DE
Germany
Prior art keywords
cells
mouse
monoclonal antibody
antibody
hybridoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE198080304350T
Other languages
German (de)
English (en)
Inventor
Gideon Short Hills New Jersey Goldstein
Patrick Chung-Shu Bridgewater New Jersey Kung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22277974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE30815(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of DE30815T1 publication Critical patent/DE30815T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hybrid Cells (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE198080304350T 1979-12-04 1980-12-03 Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches prothymozyt-antigen Pending DE30815T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/100,072 US4364935A (en) 1979-12-04 1979-12-04 Monoclonal antibody to a human prothymocyte antigen and methods of preparing same

Publications (1)

Publication Number Publication Date
DE30815T1 true DE30815T1 (de) 1984-07-19

Family

ID=22277974

Family Applications (2)

Application Number Title Priority Date Filing Date
DE198080304350T Pending DE30815T1 (de) 1979-12-04 1980-12-03 Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches prothymozyt-antigen
DE8080304350T Expired DE3070655D1 (en) 1979-12-04 1980-12-03 Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, method of preparation of this antibody, diagnostic and therapeutic uses, and pharmaceutical compositions comprising this antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8080304350T Expired DE3070655D1 (en) 1979-12-04 1980-12-03 Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, method of preparation of this antibody, diagnostic and therapeutic uses, and pharmaceutical compositions comprising this antibody

Country Status (22)

Country Link
US (1) US4364935A (enExample)
EP (1) EP0030815B1 (enExample)
JP (2) JPS5695123A (enExample)
AT (1) ATE13317T1 (enExample)
AU (1) AU545223B2 (enExample)
CA (1) CA1183470A (enExample)
DE (2) DE30815T1 (enExample)
DK (1) DK153954C (enExample)
ES (1) ES8303097A1 (enExample)
FI (1) FI75365C (enExample)
GR (1) GR72923B (enExample)
HK (1) HK24386A (enExample)
IE (1) IE50725B1 (enExample)
IL (1) IL61624A (enExample)
MY (1) MY8600519A (enExample)
NO (1) NO159888C (enExample)
NZ (1) NZ195647A (enExample)
PH (1) PH17510A (enExample)
PT (1) PT72146B (enExample)
SG (1) SG7386G (enExample)
YU (1) YU45078B (enExample)
ZA (1) ZA807567B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806349A (en) * 1979-12-04 1989-02-21 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, and methods
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
JPS5823847B2 (ja) * 1981-02-06 1983-05-18 株式会社 林原生物化学研究所 抗ヒト蛋白質抗体の製造方法
DE3105150A1 (de) * 1981-02-12 1982-08-19 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Herstellung von anti-t-lymphozyten-globulin.
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
USRE32011E (en) * 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
AU555146B2 (en) * 1982-03-15 1986-09-11 Trustees Of Columbia University In The City Of New York, The Method for intorducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products materials
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US4705687A (en) * 1985-06-17 1987-11-10 Ortho Pharmaceutical (Canada) Ltd. Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor
US4970299A (en) * 1986-07-03 1990-11-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies selective for prostate cancer
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
WO1999026658A1 (en) 1997-11-24 1999-06-03 Wong Johnson T Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
FR2878852B1 (fr) * 2000-09-28 2007-02-23 Imtix Sangstat Procede de production d'immunoglobulines anti-thymocytes humains
US7653260B2 (en) 2004-06-17 2010-01-26 Carl Zeis MicroImaging GmbH System and method of registering field of view
US8582924B2 (en) 2004-06-30 2013-11-12 Carl Zeiss Microimaging Gmbh Data structure of an image storage and retrieval system
TWI423814B (zh) * 2006-09-01 2014-01-21 Genticel 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
KR102497443B1 (ko) 2014-03-28 2023-02-08 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
MX2018016265A (es) 2016-06-28 2019-07-04 Xencor Inc Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
PE20240950A1 (es) 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3728302A1 (en) 2017-12-19 2020-10-28 Xencor, Inc. Engineered il-2 fc fusion proteins
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
MX2021003765A (es) 2018-10-03 2021-07-15 Xencor Inc Proteínas il-12 de fusión a fc heterodimérico.
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
CN114085818A (zh) * 2021-11-19 2022-02-25 蔡开来 一种抗大熊猫Thy1单克隆抗体及其杂交瘤细胞株和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses

Also Published As

Publication number Publication date
AU6501280A (en) 1981-06-11
FI75365C (fi) 1988-06-09
NO159888B (no) 1988-11-07
DE3070655D1 (en) 1985-06-20
ES497425A0 (es) 1982-12-16
IL61624A0 (en) 1981-01-30
IE802511L (en) 1981-06-04
IL61624A (en) 1984-07-31
GR72923B (enExample) 1984-01-11
DK153954C (da) 1989-02-20
AU545223B2 (en) 1985-07-04
EP0030815B1 (en) 1985-05-15
IE50725B1 (en) 1986-06-25
PH17510A (en) 1984-09-07
JPS5695123A (en) 1981-08-01
MY8600519A (en) 1986-12-31
NO159888C (no) 1989-02-15
US4364935A (en) 1982-12-21
CA1183470A (en) 1985-03-05
JPS6413988A (en) 1989-01-18
ES8303097A1 (es) 1983-02-16
FI803757L (fi) 1981-06-05
JPS649999B2 (enExample) 1989-02-21
NO803661L (no) 1981-06-05
ATE13317T1 (de) 1985-06-15
JPH0159870B2 (enExample) 1989-12-20
YU306780A (en) 1984-04-30
EP0030815A2 (en) 1981-06-24
PT72146A (en) 1981-01-01
ZA807567B (en) 1982-07-28
NZ195647A (en) 1984-07-06
PT72146B (en) 1982-07-05
SG7386G (en) 1986-11-21
HK24386A (en) 1986-04-11
EP0030815A3 (en) 1981-12-30
DK517380A (da) 1981-06-05
FI75365B (fi) 1988-02-29
DK153954B (da) 1988-09-26
YU45078B (en) 1992-03-10

Similar Documents

Publication Publication Date Title
DE30815T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches prothymozyt-antigen
DE30450T1 (de) Hybridzellinie zur herstellung komplementfixierender monoklonaler antikoerper gegen menschliche suppressor-t-zellen
DE18794T1 (de) Monoklonaler antikoerper gegen menschliche helfer-t-zellen, verfahren zu seiner herstellung, ihn produzierende hybridzellinie, seine diagnostischen und therapeutischen verwendungen und diesen antikoerper enthaltende diagnostische und therapeutische zusammensetzungen.
DE30814T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches fruehes thymozyt-antigen
DE18795T1 (de) Einen monoklonalen antikoerper produzierende hybridzellinie, antikoerper und verfahren zu seiner herstellung, diesen antikoerper enthaltende therapeutische zusammensetzung und deren diagnostische und therapeutische verwendungen.
DE33578T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches t-zellen-antigen, antikoerper und verfahren.
DE3888172T2 (de) Rekombinant-antikörper.
DE33579T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches monozyt-antigen, antikoerper und verfahren.
Kubagawa et al. Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation.
DE69637148T2 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
JP4157160B2 (ja) 改変抗体可変領域の調製のための方法
US6548640B1 (en) Altered antibodies
DE4337197C1 (de) Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
DE25722T1 (de) Monoklonaler antikoerper gegen menschliche zytotoxische und suppressor-t-zellen und verfahren zu dessen herstellung.
DE69018801T2 (de) Chimärischer anti-cae-antikörper.
EP0531300B1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
DE69226990T2 (de) Tumorantigen-spezifischer Antikörper
EP0388151A1 (en) Modified antibodies
DE69133200T2 (de) Spezifisch bindende Agentien
Hathcock et al. Expression of variable exon A-, B-, and C-specific CD45 determinants on peripheral and thymic T cell populations
DE17381T1 (de) Monoklonaler antikoerper gegen menschliche t-zellen, verfahren zu seiner herstellung, ihn produzierende hybridzellinie, ihn enthaltende therapeutische zusammensetzung und ihn verwendendes diagnostisches verfahren.
Xu et al. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells
DE3856004T2 (de) Verwendung von monoclonalen rezeptoren gegen oncoproteinen zur überwachung von krebstherapie
DE163141T1 (de) Monoklonaler menschlicher anti-igg-koerper und verfahren zu seiner herstellung.
DE3416774A1 (de) Monoklonale antikoerper, verfahren zu ihrer herstellung sowie ihre verwendung